Cipla Limited has informed the Exchange regarding a press release dated December 28, 2021, titled "Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu�� (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease".